2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1403

Psychosocial Impact of Rheumatoid Arthritis Patients on Their Family Members
Abstract Number: 2172

PTPN22 Promotes TLR-Induced Amelioration of Arthritis
Abstract Number: 778

PTPN22 rs2476601 and Susceptibility to Biopsy Proven Giant Cell Arteritis (GCA) in an Australian Sample
Abstract Number: 1888

PU.1, Mitf, and Their Novel Co-Partner, Eomes, Set up a Transcription Factor Network That Is Critical for Osteoclast Differentiation
Abstract Number: 1871

Puberty and Disease Activity in JIA
Abstract Number: 1261

Pulmonary Arterial Hypertension in Patients with Anti-PM-Scl Antibody
Abstract Number: 1296

Pulse- Pediatric Update on Lupus in South Africa: Epidemiology and Management
Abstract Number: 2765

Putative Blood Biomarkers of Reversible Cerebral Vasoconstriction Syndrome
Abstract Number: 1958

Pyrrolopyrimidine Derivatives That Inhibit Binding of BAFF to Its Receptor, BR3, Are Drug Candidates for Primary Sjögren’s Syndrome
Abstract Number: 302

Qualitative Assessment of Important Long-Term Outcomes in Juvenile Idiopathic Arthritis
Abstract Number: 2013

Quality Appraisal of Educational Websites on Osteoporosis and Bone Health
Abstract Number: 2420

Quality Assessment of Controlled Trials Evaluating Chinese Herbal Medicine in Patients with Rheumatoid Arthritis: a Systematic Review
Abstract Number: 2321

Quality Improvement in the Identification of Crystals from Synovial Fluid: Hospital Laboratory Versus Rheumatology Department Evaluation
Abstract Number: 2308

Quality of Care for Cardiovascular Disease Prevention in RA: Compliance Lipid Screening Guidelines
Abstract Number: 2306

Quality of Care for Cardiovascular Prevention in RA: Compliance with Diabetes Screening Guidelines

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].